Synergistic sedation: Fatalforty DDI: Midazolam, clozapine, synergism and clozapine, sertraline, CYP2D6

Michael Hutchens, Paul Schipper, Catherine Marcucci

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This case discusses a pharmacodynamic interaction between clozapine, midazolam, fentanyl, hydromorphone, and oxycodone resulting in central nervous system depression. It also discusses a pharmacokinetic interaction between clozapine and sertraline resulting in increased bioavailability of clozapine.

Original languageEnglish (US)
Title of host publicationA Case Approach to Perioperative Drug-Drug Interactions
PublisherSpringer New York
Pages405-407
Number of pages3
ISBN (Print)9781461474951, 9781461474944
DOIs
StatePublished - Sep 15 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Synergistic sedation: Fatalforty DDI: Midazolam, clozapine, synergism and clozapine, sertraline, CYP2D6'. Together they form a unique fingerprint.

  • Cite this

    Hutchens, M., Schipper, P., & Marcucci, C. (2015). Synergistic sedation: Fatalforty DDI: Midazolam, clozapine, synergism and clozapine, sertraline, CYP2D6. In A Case Approach to Perioperative Drug-Drug Interactions (pp. 405-407). Springer New York. https://doi.org/10.1007/978-1-4614-7495-1_87